



OCUTHER

EDUCATIONAL NETWORK IN OCULAR DRUG DELIVERY AND THERAPEUTICS

1.11.2016 – 31.10.2020

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722717.

Ocular drug development is a unique field in terms of drug targets and end-points of activity, local drug administration routes, tissue barriers and pharmacokinetics, drug delivery and formulation challenges and local toxicity issues.

The project aims to educate 15 experts (ESRs) of preclinical ocular R&D to facilitate the success of the European pharmaceutical industry and research community. They will receive tailored, multi-disciplinary and inter-sectoral education, gain research experience and perform secondments in preclinical ocular drug development. The project combines new drug candidates, innovative drug delivery technologies and modern in vitro, in silico and in vivo methods. This will involve interaction between experts of ophthal-

mology, pharmaceutical scientists and companies, as well as academic and industrial partners. Thus, the next generation of researchers will have the appreciation and the necessary skills for performing multidisciplinary research and comprehend the whole value chain of ocular therapeutics.

This project presents a unique combination of innovation and education in the ocular R&D field. The ESRs and other outcomes of this project will greatly benefit the future competitiveness of European science and industry.

MORE INFORMATION:

Professor Arto Urtti,

+358 40 540 2279, arto.urtti@uef.fi

Professor Paavo Honkakoski,

+358 40 355 2490, paavo.honkakoski@uef.fi

www.ocuther.eu

